Form 8-K - Current report:
SEC Accession No. 0001213900-25-035075
Filing Date
2025-04-24
Accepted
2025-04-24 16:15:33
Documents
15
Period of Report
2025-04-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239169-8k_abpro.htm   iXBRL 8-K 32837
2 AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE, DATED APRIL 20, 2025 ea023916901ex10-1_abpro.htm EX-10.1 11354
  Complete submission text file 0001213900-25-035075.txt   267012

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abp-20250420.xsd EX-101.SCH 3854
4 XBRL DEFINITION FILE abp-20250420_def.xml EX-101.DEF 26755
5 XBRL LABEL FILE abp-20250420_lab.xml EX-101.LAB 36995
6 XBRL PRESENTATION FILE abp-20250420_pre.xml EX-101.PRE 25379
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0239169-8k_abpro_htm.xml XML 5990
Mailing Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013
Business Address 6 ST JOHNS LANE, FLOOR 5 NEW YORK NY 10013 248-890-7200
Abpro Holdings, Inc. (Filer) CIK: 0001893219 (see all company filings)

EIN.: 871013956 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41224 | Film No.: 25867527
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)